[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579557":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":7,"responsibleParty":19,"collaborators":7,"id":21,"slug":22,"hasResults":23,"nctId":24,"briefTitle":25,"officialTitle":25,"acronym":7,"eligibilityCriteria":26,"healthyVolunteers":23,"sex":27,"minAge":7,"maxAge":7,"enrollmentInfo":28,"targetDuration":7,"studyType":31,"phases":7,"briefSummary":32,"conditions":33,"keywords":7,"overallStatus":35,"whyStopped":7,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":7},{"fullName":5,"class":6},"CARsgen Therapeutics Co., Ltd.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Zevorcabtagene Autoleucel","Non-intervention",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Yajing Zhang","CONTACT","18601333856","23975701@qq.com",{"type":20,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100579557","long-term-follow-up-observational-study-in-patients-treated-with-gene-modified-t-cell-therapy-100579557",false,"NCT06825845","Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy","Inclusion Criteria:\n\n\\- 1. All patients who have received at least one GM T-cell infusion in the parent clinical study or in the post-approval setting.\n\n2\\. Patients must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. For patients incapable of providing consent, the signed ICF of their legally accepted guardians must be obtained.\n\nExclusion Criteria:\n\n* There are no specific exclusion criteria for this study.","ALL",{"count":29,"type":30},1500,"ESTIMATED","OBSERVATIONAL","This is a prospective long-term follow-up (LTFU) study to evaluate the long-term safety and survival benefit for patients who received at least one of CARsgen's GM T cell product in a clinical trial or as a commercially available product. In this study, patients will be followed for up to 15 years after last GM T-cell infusion for the evaluation of delayed adverse events (AEs), vector persistence, potential risk for integration, and survival time due to GM T-cell exposure.",[34],"Relapsed or Refractory Multiple Myeloma","NOT_YET_RECRUITING","2025-02-08",{"date":38,"type":39},"2025-02-13","ACTUAL",{"date":41,"type":30},"2025-03-31",{"date":43,"type":30},"2040-06-30",{"name":5,"class":6}]